Abstract
Recently, there has been a rapid expansion in the development of oncology therapeutics products. With significant commercial potential, cell and gene therapies have emerged as a promising advancement in the healthcare area. Immunotherapy with CAR-T cells has shown promising results in the treatment of refractory hematological malignancies. However, the successful application of CAR-T ther…